Complement activation in patients with neuromyelitis optica.
The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a...
Κύριοι συγγραφείς: | Nytrova, P, Potlukova, E, Kemlink, D, Woodhall, M, Horakova, D, Waters, P, Havrdova, E, Zivorova, D, Vincent, A, Trendelenburg, M |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2014
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Complement activation in patients with neuromyelitis optica
ανά: Nytrova, P, κ.ά.
Έκδοση: (2014) -
C3a complement split product: possible biomarker of disease activity in patients with neuromyelitis optica
ανά: Nytrova, P, κ.ά.
Έκδοση: (2013) -
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
ανά: Saadoun, S, κ.ά.
Έκδοση: (2010) -
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
ανά: Waters, P, κ.ά.
Έκδοση: (2016) -
IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica
ανά: Jacob, S, κ.ά.
Έκδοση: (2008)